中国搭建交易与价格平台 为药械“走出去”架桥铺路

Group 1 - The core viewpoint emphasizes the importance of building platforms to support Chinese pharmaceutical and medical device companies in their global expansion efforts [1] - The National Medical Insurance Administration (NMIA) is focusing on creating an international pricing system for pharmaceuticals that aligns with global market needs, providing a pricing anchor for Chinese products [1] - The China Drug Price Registration System, set to launch in December 2025, will offer authoritative and transparent market price registration services to facilitate international market entry for Chinese pharmaceutical companies [1] Group 2 - As of January 16, 2023, the China Drug Price Registration System has registered 60 companies and 22 drugs, covering various types including traditional Chinese medicine and biopharmaceuticals [2] - The China-ASEAN Regional Pharmaceutical Trading Platform has already achieved initial success, with transaction amounts exceeding 10 million RMB, facilitating the entry of quality Chinese pharmaceuticals into Southeast Asia [2] - Several other trading and pricing platforms are under construction, including the International Medical Equipment and Devices Trading Platform, which aims to promote high-quality products like coronary stents and artificial joints internationally [3]